COMMUNIQUÉS West-GlobeNewswire

PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
10/09/2025
PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma [...]
OrthoPediatrics Corp. Completes First Procedures with VerteGlide™ Spinal Growth Guidance System
10/09/2025
WARSAW, Ind., Sept. 10, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
10/09/2025
ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scores Differentiated structure of ‘2510 potentially results in best-in-class monotherapy activity in 2L+ NSCLC for PD-(L)1xVEGF [...]
Purespring Therapeutics to Participate in the 2025 BofA Healthcare Trailblazers Private Company Conference
10/09/2025
London – 10 September 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announced that members of its management team will participate in the [...]
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia
10/09/2025
BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 treated episodes (p<.05) Complete resolution of agitation was significantly higher with [...]
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation
10/09/2025
STAFFORD, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Les données publiées dans The New England Journal of Medicine démontrent que l’association de RYBREVANT®▼ (amivantamab) et de LAZCLUZE®▼ (lazertinib) serait susceptible de redéfinir les perspectives de survie dans le traitement de première
10/09/2025
Ce schéma thérapeutique combiné sans chimiothérapie pourrait ouvrir une nouvelle ère dans le traitement de première intention, avec une survie globale médiane prévue supérieure à quatre ans, dépassant ainsi de plus d’un [...]
Fangzhou and Innovent Biologics Form Strategic Alliance for AI-Powered Weight Management Solutions
10/09/2025
SHANGHAI, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, signed a strategic partnership with Innovent Biologics to [...]

Pages